<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00604435</url>
  </required_header>
  <id_info>
    <org_study_id>Endostar B-01</org_study_id>
    <secondary_id>XOBCR01</secondary_id>
    <nct_id>NCT00604435</nct_id>
  </id_info>
  <brief_title>Neoadjuvant Endostatin and Chemotherapy for Breast Cancer</brief_title>
  <official_title>Phase II Trial of Neoadjuvant Recombinant Human Endostatin, Docetaxel and Epirubicin as First-line Therapy in Patients With Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xijing Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xijing Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study was designed to determine the efficacy and safety of neoadjuvant docetaxel and&#xD;
      epirubicin (DE) with or without human recombinant endostatin (endostar) for breast cancer&#xD;
      patients. The hypothesis of this protocol is that a combined angiogenesis inhibiting therapy&#xD;
      to chemotherapy could further enhance the cytotoxic activity in breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open labelled, prospective, randomized, phase II clinical trial. A total of 60&#xD;
      patients with core-biopsy confirmed breast cancer, stage ⅡA to ⅢC, and to be treated with&#xD;
      neoadjuvant systemic therapy are eligible for entry into this study. Patients will be&#xD;
      allocated randomly to two groups to receive either 3 cycles of neoadjuvant DE and endostar or&#xD;
      3 cycles of neoadjuvant DE. All cases receive mammography, contrast-enhanced ultrasound&#xD;
      (CEUS), magnetic resonance angiography (MRA), and positron emission tomography (PET) scanning&#xD;
      pre- and post-neoadjuvant therapy, and then undergo surgical resection. The primary endpoint&#xD;
      is clinical/pathological response. The secondary endpoint is (1) the safety and tolerability&#xD;
      of the regimens, (2) the role of mammography, CEUS, MRA and PET for response evaluation, and&#xD;
      (3) angiogenic profile and biological information involved in tumor response.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2008</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>clinical/pathological response</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>safety and tolerability</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">69</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>neoadjuvant therapy with 3 cycles of Docetaxel and Epirubicin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>chemotherapy plus endostatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>neoadjuvant therapy with 3 cycles of Docetaxel and Epirubicin plus endostatin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel and epirubicin</intervention_name>
    <description>docetaxel 75mg/m2, IV (in the vein) on day 1 of each 21 day cycle; epirubicin 60 mg/m2, IV (in the vein) on day 1 of each 21 day cycle, totally 3 cycles</description>
    <arm_group_label>chemotherapy</arm_group_label>
    <other_name>docetaxel, Sanofi-Aventis</other_name>
    <other_name>epirubicin, Pfizer</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel and epirubicin plus endostatin</intervention_name>
    <description>docetaxel 75mg/m2, IV (in the vein) on day 1 of each 21 day cycle; epirubicin 60 mg/m2, IV (in the vein) on day 1 of each 21 day cycle; endostatin 7.5mg/m2, IV (in the vein) on 1st to 14th days of each 21 day cycle; every 3 weeks, totally 3 cycles</description>
    <arm_group_label>chemotherapy plus endostatin</arm_group_label>
    <other_name>recombinant human endostatin, Simcere Co. China</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed invasive breast cancer (core needle biopsy for breast cancer&#xD;
             diagnosis and fine needle aspiration for lymph node metastasis diagnosis)&#xD;
&#xD;
          -  Stage ⅡA-ⅢC&#xD;
&#xD;
          -  Age 18-70&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  No evidence of distant metastasis&#xD;
&#xD;
          -  No previous therapy&#xD;
&#xD;
          -  Normal hematologic function&#xD;
&#xD;
          -  left ventricular ejection fraction greater than 50 percent&#xD;
&#xD;
          -  No abnormality of renal or liver function&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  With allergic constitution or possible allergic reflection to drugs to be used in this&#xD;
             study&#xD;
&#xD;
          -  Any concurrent uncontrolled medical or psychiatric disorder&#xD;
&#xD;
          -  History of severe heart diseases, including congestive heart failure, unstable angina,&#xD;
             uncontrolled arrhythmia, myocardial infarction, uncontrolled high blood pressure, or&#xD;
             heart valve disease.&#xD;
&#xD;
          -  History of bleeding diathesis&#xD;
&#xD;
          -  Being pregnant or nursing&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ling Wang, MD</last_name>
    <role>Study Director</role>
    <affiliation>Air Force Military Medical University, China</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jianghao Chen, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Air Force Military Medical University, China</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Xijing Hospital, Fourth Military Medical University</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <zip>710032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Li J, Dong X, Xu Z, Jiang X, Jiang H, Krissansen GW, Sun X. Endostatin gene therapy enhances the efficacy of paclitaxel to suppress breast cancers and metastases in mice. J Biomed Sci. 2008 Jan;15(1):99-109. Epub 2007 Aug 18.</citation>
    <PMID>17705027</PMID>
  </reference>
  <verification_date>January 2010</verification_date>
  <study_first_submitted>January 16, 2008</study_first_submitted>
  <study_first_submitted_qc>January 29, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 30, 2008</study_first_posted>
  <last_update_submitted>January 18, 2010</last_update_submitted>
  <last_update_submitted_qc>January 18, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 20, 2010</last_update_posted>
  <responsible_party>
    <name_title>Dai-Ming Fan, Principal of Fourth Military Medical University</name_title>
    <organization>Fourth Military Medical University</organization>
  </responsible_party>
  <keyword>breast cancer</keyword>
  <keyword>neoadjuvant chemotherapy</keyword>
  <keyword>docetaxel</keyword>
  <keyword>epirubicin</keyword>
  <keyword>recombinant human endostatin (endostar)</keyword>
  <keyword>chemotherapy</keyword>
  <keyword>endostatin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Epirubicin</mesh_term>
    <mesh_term>Endostatins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

